サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463099

胃不全麻痺治療薬市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、疾患クラス別、エンドユーザー別、地域別、セグメント別予測、2024年～2032年

Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024- 2032

出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
胃不全麻痺治療薬市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、疾患クラス別、エンドユーザー別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、胃不全麻痺治療薬の世界市場規模は2032年までに66億6,235万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

胃不全麻痺治療薬市場は、需要増加と市場拡大に寄与するいくつかの要因によって、世界的に着実な成長を遂げています。胃の排出遅延を特徴とする胃不全麻痺は、罹患者に大きな課題をもたらし、吐き気、嘔吐、腹部膨満感、腹部不快感などの症状を引き起こします。ヘルスケア専門家や患者の間でこの症状に対する認識が高まるにつれ、効果的な治療法に対する需要が高まり続け、胃不全麻痺治療薬市場を前進させています。

胃不全麻痺治療薬市場の成長の主な原動力の一つは、胃不全麻痺を含む胃腸障害の有病率の増加です。食習慣の変化、座りがちなライフスタイル、糖尿病の罹患率の上昇に伴い、胃不全麻痺の罹患率は世界的に上昇傾向にあります。このような患者数の急増は、製薬企業にとって、これらの患者のアンメット・メディカル・ニーズに応える新薬を開発・商品化する大きな市場機会を生み出しています。さらに、特に先進地域における高齢化も患者数の増加に寄与しており、市場の成長をさらに後押ししています。

さらに、医療技術や医薬品開発の進歩により、胃不全麻痺に対する革新的な治療法の導入が進んでいます。製薬企業は、有効性と安全性を向上させた新薬を発見・開発するため、研究開発活動に多額の投資を行っています。このような努力の結果、運動促進剤、制吐剤、胃運動障害に関与する特定の経路を標的とする薬剤など、新規の治療薬が出現しています。多様な治療オプションが利用可能になったことで、ヘルスケアプロバイダーは個々の患者のニーズに応じて治療をカスタマイズできる選択肢が増え、市場の成長を促進しています。

胃不全麻痺治療薬市場レポートハイライト

運動促進薬セグメントは2023年に注目すべきシェアを占めたが、これは胃の筋肉の収縮と運動を促進する能力による。

糖尿病性胃不全麻痺セグメントは2023年に最大シェアを占めたが、これは人々のライフスタイルや消費パターンの変化による糖尿病の著しい蔓延によるものです。

薬局セグメントは予測期間中に最も高いペースで成長すると思われるが、これは小売薬局チェーンの大幅な拡大と患者へのアクセスのしやすさに起因します。

糖尿病有病率の上昇と高度なヘルスケアインフラの存在により、北米が2023年の世界市場を席巻

主な市場プレイヤーは、Medtronic Plc、Rhythm Pharmaceuticals、Vanda Pharmaceuticals、Abbott Laboratories、AbbVie Inc.、Pfizer Inc.などです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の胃不全麻痺治療薬市場の洞察

  • 胃不全麻痺治療薬市場- エンドユーザースナップショット
  • 胃不全麻痺治療薬市場力学
    • 促進要因と機会
      • 糖尿病と高齢者人口の増加が市場の成長を後押し
      • 胃不全麻痺治療のための新薬の規制当局による承認により、市場の成長が促進されます。
    • 抑制要因と課題
      • 新たな治療法の選択肢の欠如と成長を抑制する規制上のハードル
  • PESTEL分析
  • 胃不全麻痺治療薬市場のエンドユーザーの動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 疾患クラス別の世界市場

  • 主な調査結果
  • イントロダクション
  • 糖尿病性胃不全麻痺
  • 特発性胃不全麻痺
  • 術後胃不全麻痺
  • その他

第6章 薬剤クラス別の世界市場

  • 主な調査結果
  • イントロダクション
  • 消化管運動促進剤
  • 制吐剤
  • ボツリヌス毒素注射

第7章 エンドユーザー別の世界市場

  • 主な調査結果
  • イントロダクション
  • 病院
  • 薬局
  • クリニック
  • eコマース

第8章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • 胃不全麻痺治療薬市場評価、地域、2019-2032年
  • 胃不全麻痺治療薬市場-北米
    • 北米：胃不全麻痺治療薬市場、疾患クラス別、2019年～2032年
    • 北米：胃不全麻痺治療薬市場、エンドユーザー別、2019年～2032年
    • 北米：胃不全麻痺治療薬市場、薬剤クラス別、2019年～2032年
    • 胃不全麻痺治療薬市場-米国
    • 胃不全麻痺治療薬市場- カナダ
  • 胃不全麻痺治療薬市場- 欧州
    • 欧州：胃不全麻痺治療薬市場、疾患クラス別、2019-2032年
    • 欧州：胃不全麻痺治療薬市場、エンドユーザー別、2019-2032年
    • 欧州：胃不全麻痺治療薬市場、薬剤クラス別、2019-2032年
    • 胃不全麻痺治療薬市場- 英国
    • 胃不全麻痺治療薬市場- フランス
    • 胃不全麻痺治療薬市場- ドイツ
    • 胃不全麻痺治療薬市場- イタリア
    • 胃不全麻痺治療薬市場- スペイン
    • 胃不全麻痺治療薬市場- オランダ
    • 胃不全麻痺治療薬市場- ロシア
  • 胃不全麻痺治療薬市場- アジア太平洋地域
    • アジア太平洋地域：胃不全麻痺治療薬市場、疾患クラス別、2019年～2032年
    • アジア太平洋地域：胃不全麻痺治療薬市場、エンドユーザー別、2019年～2032年
    • アジア太平洋地域：胃不全麻痺治療薬市場、薬剤クラス別、2019年～2032年
    • 胃不全麻痺治療薬市場- 中国
    • 胃不全麻痺治療薬市場- インド
    • 胃不全麻痺治療薬市場- マレーシア
    • 胃不全麻痺治療薬市場- 日本
    • 胃不全麻痺治療薬市場- インドネシア
    • 胃不全麻痺治療薬市場- 韓国
  • 胃不全麻痺治療薬市場-中東およびアフリカ
    • 中東およびアフリカ：胃不全麻痺治療薬市場、疾患クラス別、2019-2032年
    • 中東およびアフリカ：胃不全麻痺治療薬市場、エンドユーザー別、2019-2032年
    • 中東およびアフリカ：胃不全麻痺治療薬市場、薬剤クラス別、2019-2032年
    • 胃不全麻痺治療薬市場- サウジアラビア
    • 胃不全麻痺治療薬市場-UAE
    • 胃不全麻痺治療薬市場- イスラエル
    • 胃不全麻痺治療薬市場- 南アフリカ
  • 胃不全麻痺治療薬市場-ラテンアメリカ
    • ラテンアメリカ：胃不全麻痺治療薬市場、疾患クラス別、2019年～2032年
    • ラテンアメリカ：胃不全麻痺治療薬市場、エンドユーザー別、2019-2032年
    • ラテンアメリカ：胃不全麻痺治療薬市場、薬剤クラス別、2019年～2032年
    • 胃不全麻痺治療薬市場- メキシコ
    • 胃不全麻痺治療薬市場- ブラジル
    • 胃不全麻痺治療薬市場- アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第10章 企業プロファイル

  • Abbott Laboratories（US）
  • AbbVie Inc.（US）
  • Allergan Inc.（US）
  • Evoke Pharma（US）
  • Medtronic Plc（Ireland）
  • Neurogastrx Inc.（US）
  • Pfizer Inc.（US）
  • Rhythm Pharmaceuticals Inc.（US）
  • Salix Pharmaceuticals（US）
  • TEVA Pharmaceutical（Israel）
  • Vanda Pharmaceuticals Inc.（US）
図表

List of Tables

  • Table 1 Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 2 Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 3 Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 4 Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 6 North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 7 North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 8 U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 9 U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 10 U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 11 Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 12 Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 13 Canada: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 14 Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 15 Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 16 Europe: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 17 UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 18 UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 19 UK: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 20 France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 21 France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 22 France: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 23 Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 24 Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 25 Germany: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 26 Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 27 Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 28 Italy: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 29 Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 30 Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 31 Spain: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 32 Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 33 Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 34 Netherlands: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 35 Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 36 Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 37 Russia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 41 China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 42 China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 43 China: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 44 India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 45 India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 46 India: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 47 Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 48 Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 49 Malaysia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 50 Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 51 Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 52 Japan: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 53 Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 54 Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 55 Indonesia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 56 South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 57 South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 58 South Korea: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 65 UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 66 UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 67 UAE: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 68 Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 69 Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 70 Israel: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 71 South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 72 South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 73 South Africa: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 74 Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 75 Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 76 Latin America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 77 Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 78 Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 79 Mexico: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 80 Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 81 Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 82 Brazil: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • Table 83 Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • Table 84 Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • Table 85 Argentina: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Gastroparesis Drugs Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Gastroparesis Drugs Market, by Drug Class, 2022 & 2032 (USD Million)
  • Figure 8. Market by Disease Class
  • Figure 9. Global Gastroparesis Drugs Market, by Disease Class, 2022 & 2032 (USD Million)
  • Figure 10. Market by End User
  • Figure 11. Global Gastroparesis Drugs Market, by End User, 2022 & 2032 (USD Million)
  • Figure 12. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Gastroparesis Drugs Market
目次
Product Code: PM4776

The global gastroparesis drugs market size is expected to reach USD 6,662.35 Million by 2032, according to a new study by Polaris Market Research. The report "Gastroparesis Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections); By Disease Class; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The gastroparesis drugs market has been experiencing steady growth globally, driven by several factors contributing to increased demand and market expansion. Gastroparesis, a condition characterized by delayed emptying of the stomach, poses significant challenges for affected individuals, leading to symptoms such as nausea, vomiting, bloating, and abdominal discomfort. As awareness about this condition grows among healthcare professionals and patients alike, the demand for effective treatments continues to rise, propelling the gastroparesis drugs market forward.

One of the primary driving factors behind the growth of the gastroparesis drugs market is the increasing prevalence of gastrointestinal disorders, including gastroparesis. With changing dietary habits, sedentary lifestyles, and rising incidences of diabetes, the incidence of gastroparesis is on the rise globally. This surge in patient numbers has created a substantial market opportunity for pharmaceutical companies to develop and commercialize novel drugs catering to the unmet medical needs of these individuals. Moreover, the aging population, particularly in developed regions, contributes to the growing patient pool, further boosting market growth.

Furthermore, advancements in medical technology and drug development have led to the introduction of innovative treatment options for gastroparesis. Pharmaceutical companies are investing significantly in research and development activities to discover and develop new drugs with improved efficacy and safety profiles. These efforts have resulted in the emergence of novel therapeutic agents, including prokinetic agents, antiemetics, and other drugs targeting specific pathways involved in gastric motility disorders. The availability of a diverse range of treatment options provides healthcare providers with more choices to tailor therapy according to individual patient needs, thereby driving market growth.

Gastroparesis Drugs Market Report Highlights

Prokinetic agents segment accounted for noteworthy share in 2023, that is due to its ability to boost stomach muscles contractions and movement

Diabetic gastroparesis segment held the maximum share in 2023, owing to significant prevalence of diabetes due to change in people lifestyle and consumption patterns

Pharmacies segment will grow at highest pace during forecast period, that is attributed to significant expansion of retail pharmacy chains and easy accessibility to patients

North America dominated the global market in 2023, on account of rising prevalence of diabetes and presence of advanced healthcare infrastructure

The key market players include Medtronic Plc, Rhythm Pharmaceuticals, Vanda Pharmaceuticals, Abbott Laboratories, AbbVie Inc., and Pfizer Inc.

Polaris Market Research has segmented the gastroparesis drugs market report based on drug class, disease class, end user, and region:

Gastroparesis Drugs, Drug Class Outlook (Revenue - USD Million, 2023 - 2032)

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Gastroparesis Drugs, Disease Class Outlook (Revenue - USD Million, 2023 - 2032)

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Gastroparesis Drugs, End User Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospitals
  • Pharmacies
  • Clinics
  • E-commerce

Gastroparesis Drugs, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Gastroparesis Drugs Market Insights

  • 4.1. Gastroparesis Drugs Market - End User Snapshot
  • 4.2. Gastroparesis Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of diabetes and geriatric population to boost market growth
      • 4.2.1.2. Regulatory approvals for new drugs for gastroparesis treatment to boost market growth.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of novel treatment options and regulatory hurdles to restrain growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Gastroparesis Drugs Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Gastroparesis Drugs Market, by Disease Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
  • 5.3. Diabetic Gastroparesis
    • 5.3.1. Global Gastroparesis Drugs Market, by Diabetic Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.4. Idiopathic Gastroparesis
    • 5.4.1. Global Gastroparesis Drugs Market, by Idiopathic Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.5. Post-surgical Gastroparesis
    • 5.5.1. Global Gastroparesis Drugs Market, by Post-surgical Gastroparesis, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Gastroparesis Drugs Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Gastroparesis Drugs Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 6.3. Prokinetic Agents
    • 6.3.1. Global Gastroparesis Drugs Market, by Prokinetic Agents, by Region, 2019-2032 (USD Million)
  • 6.4. Antiemetic Agents
    • 6.4.1. Global Gastroparesis Drugs Market, by Antiemetic Agents, by Region, 2019-2032 (USD Million)
  • 6.5. Botulinum Toxin Injections
    • 6.5.1. Global Gastroparesis Drugs Market, by Botulinum Toxin Injections, by Region, 2019-2032 (USD Million)

7. Global Gastroparesis Drugs Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Global Gastroparesis Drugs Market, by Hospitals, By Region, 2019-2032 (USD Million)
  • 7.4. Pharmacies
    • 7.4.1. Global Gastroparesis Drugs Market, by Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Clinics
    • 7.5.1. Global Gastroparesis Drugs Market, by Clinics, By Region, 2019-2032 (USD Million)
  • 7.6. E-commerce
    • 7.6.1. Global Gastroparesis Drugs Market, by E-commerce, By Region, 2019-2032 (USD Million)

8. Global Gastroparesis Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Gastroparesis Drugs Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Gastroparesis Drugs Market - North America
    • 8.3.1. North America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.3.2. North America: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.4. Gastroparesis Drugs Market - U.S.
      • 8.3.4.1. U.S.: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.3.5. Gastroparesis Drugs Market - Canada
      • 8.3.5.1. Canada: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.4. Gastroparesis Drugs Market - Europe
    • 8.4.1. Europe: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.4. Gastroparesis Drugs Market - UK
      • 8.4.4.1. UK: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.5. Gastroparesis Drugs Market - France
      • 8.4.5.1. France: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.6. Gastroparesis Drugs Market - Germany
      • 8.4.6.1. Germany: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.7. Gastroparesis Drugs Market - Italy
      • 8.4.7.1. Italy: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.8. Gastroparesis Drugs Market - Spain
      • 8.4.8.1. Spain: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.9. Gastroparesis Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.4.10. Gastroparesis Drugs Market - Russia
      • 8.4.10.1. Russia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.5. Gastroparesis Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.4. Gastroparesis Drugs Market - China
      • 8.5.4.1. China: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.5. Gastroparesis Drugs Market - India
      • 8.5.5.1. India: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.6. Gastroparesis Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.7. Gastroparesis Drugs Market - Japan
      • 8.5.7.1. Japan: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.8. Gastroparesis Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.5.9. Gastroparesis Drugs Market - South Korea
      • 8.5.9.1. South Korea: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.6. Gastroparesis Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.4. Gastroparesis Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.5. Gastroparesis Drugs Market - UAE
      • 8.6.5.1. UAE: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.6. Gastroparesis Drugs Market - Israel
      • 8.6.6.1. Israel: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.6.7. Gastroparesis Drugs Market - South Africa
      • 8.6.7.1. South Africa: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
  • 8.7. Gastroparesis Drugs Market - Latin America
    • 8.7.1. Latin America: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.4. Gastroparesis Drugs Market - Mexico
      • 8.7.4.1. Mexico: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.5. Gastroparesis Drugs Market - Brazil
      • 8.7.5.1. Brazil: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)
    • 8.7.6. Gastroparesis Drugs Market - Argentina
      • 8.7.6.1. Argentina: Gastroparesis Drugs Market, by Disease Class, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Gastroparesis Drugs Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Gastroparesis Drugs Market, by Drug Class, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories (US)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AbbVie Inc. (US)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Allergan Inc. (US)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Evoke Pharma (US)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Medtronic Plc (Ireland)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Neurogastrx Inc. (US)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pfizer Inc. (US)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Rhythm Pharmaceuticals Inc. (US)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Salix Pharmaceuticals (US)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. TEVA Pharmaceutical (Israel)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Vanda Pharmaceuticals Inc. (US)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development